1. Home
  2. SOAR vs LYRA Comparison

SOAR vs LYRA Comparison

Compare SOAR & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Volato Group Inc.

SOAR

Volato Group Inc.

HOLD

Current Price

$0.47

Market Cap

5.3M

Sector

Finance

ML Signal

HOLD

Logo Lyra Therapeutics Inc.

LYRA

Lyra Therapeutics Inc.

HOLD

Current Price

$1.55

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOAR
LYRA
Founded
2021
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
5.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SOAR
LYRA
Price
$0.47
$1.55
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$16.00
AVG Volume (30 Days)
5.4M
147.6K
Earning Date
03-30-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.32
N/A
Revenue
$58,312,000.00
$600,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.39
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.41
$1.51
52 Week High
$6.48
$37.50

Technical Indicators

Market Signals
Indicator
SOAR
LYRA
Relative Strength Index (RSI) 36.98 31.57
Support Level $0.42 $1.73
Resistance Level $0.51 $2.05
Average True Range (ATR) 0.11 0.26
MACD 0.01 0.02
Stochastic Oscillator 8.95 3.87

Price Performance

Historical Comparison
SOAR
LYRA

About SOAR Volato Group Inc.

Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Share on Social Networks: